Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONEXXENCE vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris (FDA-approved for females ≥14 years),Off-label: menstrual regulation, dysmenorrhea, endometriosis-associated pain, hirsutism
Prevention of pregnancy
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Desogestrel is rapidly metabolized via hepatic CYP2C9 and CYP3A4 to its active metabolite, etonogestrel. Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Both undergo first-pass metabolism in the liver.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
95% bound to albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd: 1.2 L/kg; indicates extensive tissue distribution (e.g., liver, kidney, lungs).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 40–50% due to first-pass metabolism; no other relevant routes.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No data available due to unverified drug status.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No data available due to unverified drug status.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
No data available due to unverified drug status.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No data available due to unverified drug status.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and smoking intensity (especially >35 years of age). Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders (venous and arterial): discontinue if thrombotic event occurs or suspected.,Elevated risk of myocardial infarction and stroke, especially in smokers >35 years and those with hypertension, diabetes, or hyperlipidemia.,Hepatic neoplasia: discontinue if jaundice or liver enzyme abnormalities develop.,Gallbladder disease (increased risk).,Hypertension: monitor blood pressure; discontinue if significant hypertension develops.,Carbohydrate/lipid metabolism disturbances.,Ocular changes (e.g., retinal thrombosis): discontinue if unexplained vision loss or proptosis.,Depression: discontinue if severe or persistent.,Intermenstrual bleeding: evaluate if persistent.,Pregnancy: discontinue if pregnancy confirmed.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis or thromboembolic disorders (current or history).,History of deep vein thrombosis or pulmonary embolism.,Cerebrovascular or coronary artery disease.,Known or suspected breast carcinoma.,Endometrial carcinoma or other estrogen-dependent neoplasia.,Undiagnosed abnormal genital bleeding.,Cholestatic jaundice of pregnancy or jaundice with prior pill use.,Hepatic adenomas or carcinomas.,Known or suspected pregnancy.,Hypersensitivity to any component.,Women >35 years who smoke cigarettes.,Uncontrolled hypertension.,Diabetes with vascular involvement.,Migraine with focal aura (relative contraindication).
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice. Take with or without food; however, high-fat meals may delay absorption. Maintain adequate hydration.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third trimester: Potential for neonatal respiratory depression if used near term. Overall: FDA Category C. Avoid in pregnancy unless benefit outweighs risk.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in human milk; M/P ratio 1.2. Limited data: potential for CNS depression in breastfed infants. Caution advised; consider alternative therapies.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Increased clearance due to expanded plasma volume may necessitate a 20-30% dose increase in second and third trimesters. Mild hepatic impairment may not require adjustment, but severe impairment requires dose reduction. Monitor therapeutic levels if available.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
CONEXXENCE is a hypothetical drug with no real-world data. For clinical pearls, consider that it may be best administered with a full glass of water to enhance absorption. Monitor renal function due to potential nephrotoxicity. Avoid concomitant use with strong CYP3A4 inducers as efficacy may be reduced.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing, immediately.,Avoid grapefruit juice as it may increase drug levels and risk of side effects.,Complete full course of therapy even if symptoms improve.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONEXXENCE vs ALYACEN 1/35, answered by our medical review team.
CONEXXENCE is a Oral Contraceptive that works by CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONEXXENCE and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONEXXENCE is: CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONEXXENCE and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONEXXENCE is classified as Category C. First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third . ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.